ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 187,65
0,69%
Dow Jones
39 387,76
0,85%
DAX
18 686,60
1,07%
Brent Oil
83,95
0,47%
Bitcoin
62 719,83
2,50%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Maxcyte Inc (MXCT)

  7. Maxcyte Inc (MXCT) Actualités

MXCT

Maxcyte (MXCT)

Maxcyte Inc
De:
Trier par:
 Showing the most relevant articles for your search:LSE:MXCT
DateHeureSourceTitreSymboleSociété
08/05/202410h46Alliance NewsAlliance NewsMaxCyte shares rise amid double-digit revenue increaseLSE:MXCTMaxcyte Inc
08/05/202408h05RNS Regulatory NewsMaxCyte, Inc. Filing of Form 10-QLSE:MXCTMaxcyte Inc
08/05/202408h00RNS Regulatory NewsMaxCyte, Inc. First Quarter ResultsLSE:MXCTMaxcyte Inc
03/05/202408h00RNS Regulatory NewsMaxCyte, Inc. Notice of AGMLSE:MXCTMaxcyte Inc
01/05/202418h04RNS Regulatory NewsMaxCyte, Inc. Total Voting RightsLSE:MXCTMaxcyte Inc
10/04/202414h05RNS Regulatory NewsMaxCyte, Inc. Notice of ResultsLSE:MXCTMaxcyte Inc
03/04/202408h00RNS Regulatory NewsMaxCyte, Inc. Total Voting Rights and Block Listing ReturnLSE:MXCTMaxcyte Inc
02/04/202416h19Alliance NewsAlliance NewsTRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmoutLSE:MXCTMaxcyte Inc
02/04/202414h05RNS Regulatory NewsMaxCyte, Inc. Signing of Strategic Platform LicenseLSE:MXCTMaxcyte Inc
02/04/202408h00RNS Regulatory NewsMaxCyte, Inc. Exercise of options and PDMR dealingLSE:MXCTMaxcyte Inc
20/03/202411h16RNS Regulatory NewsMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR DealingLSE:MXCTMaxcyte Inc
13/03/202412h54Alliance NewsAlliance NewsIN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%LSE:MXCTMaxcyte Inc
13/03/202408h05RNS Regulatory NewsMaxCyte, Inc. Filing of form 10-K for FY ended December 31, 2023LSE:MXCTMaxcyte Inc
13/03/202408h00RNS Regulatory NewsMaxCyte, Inc. Reports Q4 & FY 2023 Financial ResultsLSE:MXCTMaxcyte Inc
12/03/202421h05UK RegulatoryMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceLSE:MXCTMaxcyte Inc
06/03/202409h58RNS Regulatory NewsMaxCyte, Inc. TR-1: Notification of major holdingsLSE:MXCTMaxcyte Inc
05/03/202421h43Alliance NewsAlliance NewsEARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profitLSE:MXCTMaxcyte Inc
05/03/202408h00RNS Regulatory NewsMaxCyte, Inc. Preliminary FY Results & 2024 GuidanceLSE:MXCTMaxcyte Inc
04/03/202422h05UK RegulatoryMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsLSE:MXCTMaxcyte Inc
09/02/202414h05UK RegulatoryMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesLSE:MXCTMaxcyte Inc
31/01/202408h00RNS Regulatory NewsMaxCyte, Inc. Director/PDMR ShareholdingLSE:MXCTMaxcyte Inc
30/01/202415h29RNS Regulatory NewsMaxCyte, Inc. Holding(s) in CompanyLSE:MXCTMaxcyte Inc
30/01/202414h58Alliance NewsAlliance NewsIN BRIEF: MaxCyte signs licencing deal with cell therapy company WugenLSE:MXCTMaxcyte Inc
30/01/202414h05UK RegulatoryMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersLSE:MXCTMaxcyte Inc
29/01/202418h56Alliance NewsAlliance NewsIN BRIEF: MaxCyte chief scientific officer leaves firmLSE:MXCTMaxcyte Inc
29/01/202408h00RNS Regulatory NewsMaxCyte, Inc. Filing of Form 8-KLSE:MXCTMaxcyte Inc
23/01/202419h39Alliance NewsAlliance NewsTRADING UPDATES: Esken's Southend Airport faces further allegationsLSE:MXCTMaxcyte Inc
09/01/202413h18Alliance NewsAlliance NewsMaxCyte's strategic platform licences redeem otherwise modest resultsLSE:MXCTMaxcyte Inc
09/01/202408h00UK RegulatoryMaxCyte, Inc. Preliminary Unaudited Q4 and FY 2023 ResultsLSE:MXCTMaxcyte Inc
05/01/202408h00UK RegulatoryMaxCyte, Inc. Grant of Options and PDMR DealingLSE:MXCTMaxcyte Inc
 Showing the most relevant articles for your search:LSE:MXCT

Dernières Valeurs Consultées

NYSE
JPM
JP Morgan Chase
NYSE
KO
Coca Cola
EU
CS
Axa
EU
MC
Lvmh Moet Hennessy Louis...
EU
CAP
Capgemini
EU
LR
Legrand
NYSE
NKE
Nike
EU
ACA
Credit Agricole
SPI
SP500
S&P 500
EU
PX1
CAC 40
EU
ORA
Orange
NYSE
MCD
McDonalds
EU
DG
Vinci
EU
BN
Danone
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés